<DOC>
	<DOCNO>NCT00436618</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth cancer cell block enzymes need cell growth block blood flow cancer . PURPOSE : This phase II trial study side effect well everolimus work treat patient lymphoma relapse respond previous treatment .</brief_summary>
	<brief_title>Everolimus Treating Patients With Lymphoma That Has Relapsed Not Responded Previous Treatment</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess tumor response patient relapse refractory indolent non-Hodgkin lymphoma ( close accrual 8/18/08 ) , aggressive non-Hodgkin 's lymphoma ( close accrual 2/7/08 except diffuse large B cell lymphoma , grade III follicular lymphoma , transform lymphoma ) , uncommon lymphoma ( close accrual 9/2/08 ) , include Hodgkin 's lymphoma , treat everolimus . Secondary - Evaluate overall survival , progression-free survival , time disease progression patient treat drug . OUTLINE : This multicenter study . Patients stratify accord histology ( aggressive lymphoma [ close accrual 2/7/08 except diffuse large B cell lymphoma , grade III follicular lymphoma , transform lymphoma ] v indolent lymphoma [ close accrual 8/18/08 ] v uncommon lymphoma [ close accrual 9/2/08 ] ) . Patient receive oral everolimus daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo blood tissue collection baseline periodically study treatment translational research study . Blood tissue sample analyze biomarkers study effect everolimus lymphoma . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven* relapse refractory lymphoma , include follow : Aggressive lymphoma ( close accrual 2/7/08 except diffuse large B cell lymphoma , grade III follicular lymphoma , transform lymphoma ) Transformed lymphoma Diffuse large Bcell lymphoma Mantle cell lymphoma Grade 3 follicular lymphoma Precursor Bcell lymphoblastic leukemia/lymphoma Mediastinal ( thymic ) large Bcell lymphoma Burkitt 's lymphoma/leukemia Precursor Tcell lymphoblastic leukemia/lymphoma Primary cutaneous anaplastic large cell lymphoma Primary systemic type anaplastic large cell lymphoma Indolent lymphoma ( close accrual 8/18/08 ) Small lymphocytic lymphoma/chronic lymphocytic leukemia Grade 1 2 follicular lymphoma Extranodal marginal zone Bcell lymphoma MALT type Nodal marginal zone Bcell lymphoma Splenic marginal zone Bcell lymphoma Uncommon lymphoma ( close accrual 9/2/08 ) Unspecified peripheral Tcell lymphoma Anaplastic large cell lymphoma ( T null cell type ) Lymphoplasmacytic lymphoma ( Waldenstrom 's macroglobulinemia ) Central Nervous System ( CNS ) lymphoma Posttransplant lymphoproliferative disorder Mycosis fungoides/Sezary syndrome Hodgkin 's lymphoma Primary effusion lymphoma Blastic Natural Killer ( NK ) cell lymphoma Adult Tcell leukemia/lymphoma Nasal type extranodal NK/Tcell lymphoma Enteropathy type Tcell lymphoma Hepatosplenic Tcell lymphoma Subcutaneous panniculitislike Tcell lymphoma Angioimmunoblastic Tcell lymphoma NOTE : *Biopsies perform &lt; 6 month prior study entry allow ; biopsyproven CNS lymphoma ( time ) require rebiopsy order eligible study Previously treat disease Patients aggressive lymphoma ( close accrual 8/24/07 ) OR Hodgkin 's lymphoma must receive ineligible potentially curative therapy , include stem cell transplantation Measurable disease** CT scan MRI , define 1 following : At least 1 unidimensionally measurable lesion &gt; 2 cm diameter Skin lesion may use meet criterion photograph ruler More 5,000/mm³ tumor cell blood NOTE : **For patient lymphoplasmacytic lymphoma without measurable lymphadenopathy , measurable disease may define bone marrow lymphoplasmacytosis &gt; 10 % lymphoplasmacytic cell aggregate , sheet , lymphocyte , plasma cell , lymphoplasmacytic cell bone marrow biopsy AND quantitative Immunoglobulin M ( IgM ) monoclonal protein &gt; 1,000 mg/dL PATIENT CHARACTERISTICS : Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy &gt; 3 month Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 75,000/mm³ Hemoglobin ≥ 8 g/dL Total bilirubin ≤ 2 time upper limit normal ( ULN ) OR direct bilirubin ≤ 1.5 time ULN aspartate aminotransferase ( AST ) ≤ 3 time ULN ( 5 time ULN liver involvement present ) Creatinine ≤ 2 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Willing provide blood sample portion bone marrow aspirate biopsy study participation Able swallow intact study medication tablets No lifethreatening illness ( unrelated tumor ) No serious nonmalignant disease ( e.g. , active infection condition ) , opinion investigator , would preclude study participation No active malignancy require treatment would preclude study participation No known HIV positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 week since prior myelosuppressive chemotherapy biologic therapy ( unless patient recover nadir previous treatment ) More 3 week since prior radiotherapy ( unless acute side effect associate therapy resolve ) Concurrent stable ( i.e. , increase within past month ) chronic dos corticosteroid , maximum dose 20 mg prednisone per day , allow prescribed disorder lymphoma ( e.g. , rheumatoid arthritis , polymyalgia rheumatica , adrenal insufficiency , asthma ) Nonescalating dos steroids low possible dose level allow CNS lymphoma No concurrent investigational ancillary therapy No concurrent chemotherapy , immunotherapy , radiotherapy No concurrent participation clinical trial involve pharmacologic agent ( e.g. , drug , biologics , immunotherapy , gene therapy ) symptom control therapeutic intent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>primary central nervous system Hodgkin lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
</DOC>